Abstract
Background
Methods
Results
Acknowledgments
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Fig. 2
Forest plot of SMD for the association between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism, and funnel plots for evaluating publication bias. *TC genotype; †CC genotype; *†TC and CC genotype.
![alm-35-329-g002](/upload/SynapseXML/3039alm/thumb/alm-35-329-g002.jpg)
Fig. 3
Forest plots and funnel plots of each subgroup. (A) Forest plots of SMD for the association between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism of Chinese populations, and funnel plot for evaluating publication bias; (B) Forest plot of SMD for the association between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C heterozygous genotype, and funnel plot for evaluating publication bias; (C) Forest plot of SMD for the association between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C homozygote genotype, and funnel plotfor evaluating publication bias; (D) Forrest plot of SMD for the association between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C variant genotypes (T/C and C/C genotype), and funnel plot for evaluating publication bias. *TC genotype; †CC genotype; *†TC and CC genotype; S: simvastatin; A: atorvastatin; R: rosuvastatin; 4: 4 weeks; 8: 8 weeks.
![alm-35-329-g003](/upload/SynapseXML/3039alm/thumb/alm-35-329-g003.jpg)
Table 1
Summary of the data used in the meta-analysis
![alm-35-329-i001](/upload/SynapseXML/3039alm/thumb/alm-35-329-i001.jpg)
Please delete this line. These footnote belong to Fig. 2.
Abbreviations: ARMS, amplification refractory mutation system; AS, allele-specific; RFLP, restriction fragment length polymorphism.
Table 2
Meta-analysis results of all studies and each subgroup studies
![alm-35-329-i002](/upload/SynapseXML/3039alm/thumb/alm-35-329-i002.jpg)
*Analysis of the association between the lipid-lowering efficacy of statins and SLCO1B1 c.521T>C polymorphism; †Analysis of the association between the lipid-lowering efficacy of statins and SLCO1B1 c.521T>C polymorphism in Chinese populations; ‡Analysis of the association between the lipid-lowering efficacy of statins and SLCO1B1 variant heterozygotes (T/C); §Analysis of the association between the lipid-lowering efficacy of statins and SLCO1B1 variant homozygotes (C/C); ∥These studies did not provide the cases of single heterozygote (T/C) or homozygote (C/C).
Abbreviations: SMD, standard mean difference; CI, confidence interval.
Table 3
Main results of meta-analysis for the drug type and treatment length subgroups
![alm-35-329-i003](/upload/SynapseXML/3039alm/thumb/alm-35-329-i003.jpg)
*The data by Bailey et al. [12] were excluded. If P>1, there is no heterogeneity in simvastin subgroup.
Abbreviations: SMD, standard mean difference; CI, confidence interval.